Skip to content

IMMUCELL CORP /DE/

ICCC

CIK 0000811641 · In Vitro & In Vivo Diagnostic Substances · Nasdaq

← back to feed
Revenue (TTM)
$29.94M
+4.3% YoY Q1 May 2026
Net Income (TTM)
$3.75M
+51.8% YoY Q1 May 2026
EPS Diluted (TTM)
$0.41
+53.8% YoY Q1 May 2026
Gross Margin
44.1%
Q1 May 2026
Operating Margin
12.3%
Q1 May 2026
Net Margin
12.5%
Q1 May 2026
Free Cash Flow (TTM)
$1.54M
Q1 May 2026
Cash
$6.81M
Q1 May 2026
Total Debt
$16.93M
Q1 May 2026
Shares Outstanding
9.05M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings